Targets › BCL11A
4 programs from 4 companies in 8 trials: 5 Phase 1, 3 Phase 3; Hematology; next expected readout Jun 2027.
Transcription factor. Associated with the BAF SWI/SNF chromatin remodeling complex. (UniProt, Q9H165)
Open in Phaseline: the race on BCL11A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals | Exagamglogene Autotemcel (CTX001) B-cell lymphoma/leukemia 11A gene editing negative modulator | BCL11A | Phase 3 | Sickle Cell Disease; Beta-Thalassemia | Jun 2027 |
| Daniel Bauer | autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer t BCL11A enhancer targeting CRISPR/Cas9 gene editing | BCL11A | Phase 1 | Sickle Cell Disease | Dec 2028 |
| St. Jude Children's Research Hospital | Gene-modified CD34+ cells CRISPR/Cas9-edited CD34+ hematopoietic stem and progenitor cells (HSPCs) designed to incre | BCL11A | Phase 1 | Sickle Cell Disease | Dec 2029 |
| Editas Medicine | EDIT-301 (renizgamglogene autogedtemcel, reni-cel) ex vivo base editing of hematopoietic stem cells targeting BCL11A to increase fetal hemogl | BCL11A | Phase 1 | Sickle Cell Disease; Transfusion Dependent Beta Thalassemia | – |
Sickle Cell Disease (5) Beta-Thalassemia (2) Transfusion Dependent Beta Thalassemia (1)
other (2), protein or peptide (1), mixed (1)
Daniel Bauer (1) Vertex Pharmaceuticals (1) Editas Medicine (1) St. Jude Children's Research Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.